Fleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphonate on bydroxyapatite and its implications in calcium homeostasis. Nature. 1966;12:901-903. doi: 10.1038/212901a0..
DOI: 10.1038/212901a0
Russell R.G. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. doi: 10.1016/j.bone.2011.04.022..
DOI: 10.1016/j.bone.2011.04.022
Pols H.A., Felsenberg D., Hanley D.A. et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int. 1999;9:461–468. doi: 10.1007/PL00004171..
DOI: 10.1007/PL00004171
Black D.M., Thompson D.E., Bauer D.C. and FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85(11):4118-4124. doi: 10.1210/jcem.85.11.6953..
DOI: 10.1210/jcem.85.11.6953
Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927. Лесняк О.М., Беневоленская Л.И. (ред.). Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2009. 272 с. Lesnyak O.M., Benevolenskaya L.I. (ed.). Osteoporosis. Diagnosis, prevention and treatment. Clinical guidelines. 2nd ed., revised and updated. М.: GEOTARMedia Publishing Group; 2009. 272 p. (In Russ.).
DOI: 10.1001/jama.296.24.2927. Лесняк О.М., Беневоленская Л.И. (ред.). Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2009. 272 с. Lesnyak O.M., Benevolenskaya L.I. (ed.). Osteoporosis. Diagnosis, prevention and treatment. Clinical guidelines. 2nd ed., revised and updated. М.: GEOTARMedia Publishing Group; 2009. 272 p. (In Russ.)
Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99. doi: 10.1056/NEJMoa030897..
DOI: 10.1056/NEJMoa030897
Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., Coyle D., Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155. doi: 10.1002/14651858.CD001155.pub2..
DOI: 10.1002/14651858.CD001155.pub2
Schnitzer T., Bone H.G., Grepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res. 2000;12:1-12. doi: 10.1007/BF03339822..
DOI: 10.1007/BF03339822
Rizzoli R., Greenspan S.L., Bone G. III, Schnitzer T.J., Watts N.B., Adami S., et al. Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. J Bone Mineral Research. 2002;(11):1988-1996. doi: 10.1359/jbmr.2002.17.11.1988..
DOI: 10.1359/jbmr.2002.17.11.1988
Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., Palmisano J.J. Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, openlabel, crossover study. Clin Ther. 2002;24(11):1871-1886. doi: 10.1016/s0149-2918(02)80085-6..
DOI: 10.1016/s0149-2918(02)80085-6
Greenspan S., Field-Munves E., Tonino R., Smith M., Petruschke R., Wang L., Yates J., de Papp A.E., Palmisano J. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double- blind, placebo-controlled study. Mayo Clin Proc. 2002;77(10):1044-1052. doi: 10.4065/77.10.1044..
DOI: 10.4065/77.10.1044
Lanza F., Sahba B., Schwartz H., Winograd S., Torosis J., Quan H., Reyes R., Musliner T., Daifotis A., Leung A. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002;97(1):58-64. doi: 10.1111/j.1572-0241.2002.05446.x..
DOI: 10.1111/j.1572-0241.2002.05446.x
Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005;21(5):599-607. doi: 10.1111/j.1365-2036.2005.02378.x..
DOI: 10.1111/j.1365-2036.2005.02378.x
Мазуров В.И., Лесняк О.М., Белова К.Ю., Ершова О.Б., Зоткин Е.Г., Марченкова Л.А., Кочиш А.Ю., Рожинская Л.Я., Скрипникова И.А. Алгоритмы выбора терапии остеопороза при оказании первичной медико-санитарной помощи и организации льготного лекарственного обеспечения отдельных категорий граждан, имеющих право на получение государственной социальной помощи. Системный обзор и резолюция экспертного совета российской ассоциации по остеопорозу. Профилактическая медицина. 2019;(1):57-65. doi: 10.17116/profmed20192201157. Mazurov V.I., Lesnyak O.M., Belova K.Yu., Ershova O.B., Zotkin E.G., Marchenkova L.A., Kochish A.Yu., Rozhinskaya L.Ya., Skripnikova I.A. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine and Public Health. 2019;22(1):57-65. (In Russ.) doi: 10.17116/profmed20192201157..
DOI: 10.17116/profmed20192201157
Kanis J.A., Reginster J.Y., Kaufman J.M., Ringe J.D., Adachi J.D., Hiligsmann M., Rizzoli R., Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213-221. doi: 10.1007/s00198-011-1796-6..
DOI: 10.1007/s00198-011-1796-6
Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209-216. doi: 10.1016/s0002-9343(03)00362-0..
DOI: 10.1016/s0002-9343(03)00362-0
Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G. Clinical pharmacology of alendronate sodium. Osteopor Int. 1993;3(suppl.3):513-516. doi: 10.1007/bf01623002..
DOI: 10.1007/bf01623002
Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75-85. doi: 10.1023/A:1008626026484..
DOI: 10.1023/A:1008626026484
Invernizzi M., Cisari C., Carda S. The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res. 2015;27(2):107-113. doi: 10.1007/s40520-014-0256-5..
DOI: 10.1007/s40520-014-0256-5
Chesnut C.H. 3rd, McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152. doi: 10.1016/s0002-9343(99)80134-x..
DOI: 10.1016/s0002-9343(99)80134-x
Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets possible mechanisms. Dig Dis Sci. 1998;43(9):1998-2002. doi: 10.1023/a:1018894827961..
DOI: 10.1023/a:1018894827961
Abid S., Mumtaz K., Jafri W., Hamid S., Abbas Z., Shah H.A., Khan A.H. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005;37(8):740-744. doi: 10.1055/s-2005-870129..
DOI: 10.1055/s-2005-870129
Perkinks A.C., Blackshaw E., Hay P.D. et al. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a singlecenter single-blind, six-period crossover study in healthy female subjects. Clin Ther. 2008;30(5):834-844. doi: 10.1016/j.clinthera.2008.04.018..
DOI: 10.1016/j.clinthera.2008.04.018
Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate-prophylactic effects of rebamipide. Curr Pharm Des 2011; 17(16):1602-1611. doi: 10.2174/138161211796196927..
DOI: 10.2174/138161211796196927
Gomez Acotto C., Antonelli C., Flynn D., McDaid D., Roldan E.J. Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Calcif Tissue Int. 2012;91(5):325-334. doi: 10.1007/s00223-012-9639-9..
DOI: 10.1007/s00223-012-9639-9
Hodges L.A., Connolly S.M., Winter J., Schmidt T., Stevens H.N.E., Hayward M., Wilson C.G. Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm. 2012;432:57-62. doi: 10.1016/j.ijpharm.2012.04.073..
DOI: 10.1016/j.ijpharm.2012.04.073